Press releaseBusiness Wire
Acumen Pharmaceuticals
ABOS · NASDAQ
$2.02+$0.245 (+13.84%)TodayMarket closed ·
Prev close $1.77
Latest news
- News
Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
- News
Earnings Scheduled For May 12, 2026
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
Earnings Scheduled For March 26, 2026
- News
Market-Moving News for March 16th
- News
Earnings Scheduled For November 12, 2025
- News
Preview: Acumen Pharmaceuticals's Earnings
- Press releaseGlobe Newswire
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
- News
Earnings Scheduled For August 12, 2025
- News
Acumen Pharmaceuticals's Earnings: A Preview
- News
Earnings Scheduled For May 13, 2025
- News
A Preview Of Acumen Pharmaceuticals's Earnings
- Press releaseGlobe Newswire
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
- Press releaseGlobe Newswire
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
- News
Acumen Pharmaceuticals Earnings Preview
- Press releaseGlobe Newswire
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
- Press releaseBusiness Wire
Lucy Therapeutics Appoints Kim Drapkin as Board Chair
- Press releaseGlobe Newswire
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease
- Press releaseGlobe Newswire
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.